VBI-2902 explained
N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1]
History
In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[2] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[2] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[3] [4] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[5]
External links
- https://www.vbivaccines.com/press-releases/vbi-2902-preclinical-and-challenge-study-data/
Notes and References
- Web site: Philippidis. Alex. 2021-11-01. Six Up-and-Coming COVID-19 Vaccines. 2021-12-23. GEN - Genetic Engineering and Biotechnology News. en-US.
- Web site: VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902. VBI Vaccines. March 22, 2021. March 9, 2021.
- Web site: VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker . 2022-03-27 . covid19.trackvaccines.org.
- VBI Vaccines Inc. . 2021-10-01 . A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults .
- Curran M, Sali D, Kovessy P . Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway' . Behind the Headlines . August 2020 . March 22, 2021 . 2 May 2021 . https://web.archive.org/web/20210502170922/https://obj.ca/article/local/podcast-kemptvilles-next-boom-variation-biotechnologies-56m-injection-vanier-gateway . dead .
